(Q33405903)

26 July 2017

Intravenous immunoglobulin therapy: how does IgG modulate the immune system? (English)

1 reference

26 July 2017

Falk Nimmerjahn

2

0 references

author name string

Inessa Schwab

series ordinal

1

1 reference

PubMed ID

23411799

26 July 2017

language of work or name

1 reference

15 February 2013

1 reference

Nature Reviews Immunology

26 July 2017

1 reference

26 July 2017

13

1 reference

26 July 2017

176-189

1 reference

26 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nri3401

26 July 2017

0 references

cites work

Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation

1 reference

Intravenous immunoglobulin therapy in rheumatic diseases

31 March 2020

1 reference

Anti-inflammatory actions of intravenous immunoglobulin

31 March 2020

1 reference

Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

31 March 2020

1 reference

Roles of Fc receptors in autoimmunity

31 March 2020

1 reference

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

31 March 2020

1 reference

The antiinflammatory activity of IgG: the intravenous IgG paradox

31 March 2020

1 reference

The complement system in regulation of adaptive immunity

31 March 2020

1 reference

Fcgamma receptors as regulators of immune responses

31 March 2020

1 reference

Differential Contribution of Three Activating IgG Fc Receptors (Fc RI, Fc RIII, and Fc RIV) to IgG2a- and IgG2b-Induced Autoimmune Hemolytic Anemia in Mice

31 March 2020

1 reference

Complement: help or hindrance?

31 March 2020

1 reference

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

31 March 2020

1 reference

Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo

31 March 2020

1 reference

Cytotoxic antibodies trigger inflammation through Fc receptors

31 March 2020

1 reference

Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.

31 March 2020

1 reference

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

31 March 2020

1 reference

Fc receptors are major mediators of antibody based inflammation in autoimmunity

31 March 2020

1 reference

Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors

31 March 2020

1 reference

Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.

31 March 2020

1 reference

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

31 March 2020

1 reference

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

31 March 2020

1 reference

Divergent roles for Fc receptors and complement in vivo

31 March 2020

1 reference

Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice

31 March 2020

1 reference

Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade

31 March 2020

1 reference

FcR gamma chain deletion results in pleiotrophic effector cell defects

31 March 2020

1 reference

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

31 March 2020

1 reference

Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody

31 March 2020

1 reference

Both FcγRIV and FcγRIII are essential receptors mediating type II and type III autoimmune responsesviaFcRγ-LAT-dependent generation of C5a

31 March 2020

1 reference

A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction

31 March 2020

1 reference

Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice

31 March 2020

1 reference

Phosphoinositide 3-kinases gamma and delta, linkers of coordinate C5a receptor-Fcgamma receptor activation and immune complex-induced inflammation

31 March 2020

1 reference

C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease

31 March 2020

1 reference

Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation.

31 March 2020

1 reference

Regulation of human neutrophil Fcγ receptor IIa by C5a receptor promotes inflammatory arthritis in mice

31 March 2020

1 reference

Low-affinity Fcgamma receptors, autoimmunity and infection

31 March 2020

1 reference

FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo

31 March 2020

1 reference

Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc RI and Fc RIV

31 March 2020

1 reference

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

31 March 2020

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma

31 March 2020

1 reference

Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody

31 March 2020

1 reference

Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice

31 March 2020

1 reference

Negative signaling in Fc receptor complexes

31 March 2020

1 reference

Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice

31 March 2020

1 reference

Inhibitory pathways triggered by ITIM-containing receptors.

31 March 2020

1 reference

FcγRIIB: a modulator of cell activation and humoral tolerance.

31 March 2020

1 reference

Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE

31 March 2020

1 reference

Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy

31 March 2020

1 reference

A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus

31 March 2020

1 reference

Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts

31 March 2020

1 reference

FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling.

31 March 2020

1 reference

FcγRIIb controls bone marrow plasma cell persistence and apoptosis

31 March 2020

1 reference

Primary immunodeficiency disorders: antibody deficiency

31 March 2020

1 reference

Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes

31 March 2020

1 reference

Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy

31 March 2020

1 reference

Differences between IGIV products: impact on clinical outcome

31 March 2020

1 reference

Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content

31 March 2020

1 reference

How I treat idiopathic thrombocytopenic purpura (ITP).

31 March 2020

1 reference

Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

31 March 2020

1 reference

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

31 March 2020

1 reference

Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin

31 March 2020

1 reference

Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies

31 March 2020

1 reference

Diagnosis, treatment, and long-term management of Kawasaki disease

31 March 2020

1 reference

Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.

31 March 2020

1 reference

Guidelines on the use of intravenous immune globulin for hematologic conditions

31 March 2020

1 reference

Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

31 March 2020

1 reference

The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders

31 March 2020

1 reference

Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain

31 March 2020

1 reference

Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg).

31 March 2020

1 reference

Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations

31 March 2020

1 reference

Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).

31 March 2020

1 reference

Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass

31 March 2020

1 reference

Intravenous immunoglobulin preparations contain anti–Siglec-8 autoantibodies

31 March 2020

1 reference

Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL.

31 March 2020

1 reference

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

31 March 2020

1 reference

Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations

31 March 2020

1 reference

Current therapy of the pemphigus group

31 March 2020

1 reference

Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model

31 March 2020

1 reference

F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins

31 March 2020

1 reference

Arthritis critically dependent on innate immune system players

31 March 2020

1 reference

Protection and injury: the differing roles of complement in the development of glomerular injury

31 March 2020

1 reference

Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

31 March 2020

1 reference

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

31 March 2020

1 reference

Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.

31 March 2020

1 reference

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

31 March 2020

1 reference

IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.

31 March 2020

1 reference

Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production

31 March 2020

1 reference

The half-lives of serum immunoglobulins in adult mice.

31 March 2020

1 reference

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

31 March 2020

1 reference

Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases

31 March 2020

1 reference

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

31 March 2020

1 reference

IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.

31 March 2020

1 reference

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

31 March 2020

1 reference

The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia

31 March 2020

1 reference

Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

31 March 2020

1 reference

Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody

31 March 2020

1 reference

The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

31 March 2020

1 reference

Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?

31 March 2020

1 reference

Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia

31 March 2020

1 reference

FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin

31 March 2020

1 reference

Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia

31 March 2020

1 reference

Monoclonal anti-D is not effective in the treatment of chronic autoimmune thrombocytopenic purpura

31 March 2020

1 reference

Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D.

31 March 2020

1 reference

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

31 March 2020

1 reference

IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity

31 March 2020

1 reference

Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia

31 March 2020

1 reference

B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo

31 March 2020

1 reference

Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells

31 March 2020

1 reference

Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice

31 March 2020

1 reference

Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP.

31 March 2020

1 reference

Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.

31 March 2020

1 reference

Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb

31 March 2020

1 reference

Restoration of tolerance in lupus by targeted inhibitory receptor expression

31 March 2020

1 reference

Exposure of NK cells to intravenous immunoglobulin induces IFNγ release and degranulation but inhibits their cytotoxic activity

31 March 2020

1 reference

The impact of glycosylation on the biological function and structure of human immunoglobulins.

31 March 2020

1 reference

A close look at human IgG sialylation and subclass distribution after lectin fractionation

31 March 2020

1 reference

Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation

31 March 2020

1 reference

Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia

31 March 2020

1 reference

Analytical and Functional Aspects of Antibody Sialylation.

31 March 2020

1 reference

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

31 March 2020

1 reference

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

31 March 2020

1 reference

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

31 March 2020

1 reference

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

31 March 2020

1 reference

Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG

31 March 2020

1 reference

Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study

31 March 2020

1 reference

Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein.

31 March 2020

1 reference

Glycosylation of IgG, immune complexes and IgG subclasses in the MRL-lpr/lpr mouse model of rheumatoid arthritis

31 March 2020

1 reference

Functional analysis of agalactosyl IgG in inflammatory bowel disease patients

31 March 2020

1 reference

Siglecs and immune regulation

31 March 2020

1 reference

Siglecs as positive and negative regulators of the immune system

31 March 2020

1 reference

IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes

31 March 2020

1 reference

Identification of a receptor required for the anti-inflammatory activity of IVIG.

31 March 2020

1 reference

Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes

31 March 2020

1 reference

Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins

31 March 2020

1 reference

A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?

31 March 2020

1 reference

Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.

31 March 2020

1 reference

Intravenous immunoglobulin up-regulates the expression of the inhibitory FcgammaIIB receptor on B cells.

31 March 2020

1 reference

B cells regulate autoimmunity by provision of IL-10.

31 March 2020

1 reference

Fcgamma receptors: old friends and new family members

31 March 2020

1 reference

Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and Fc gamma RII-mediated B cell suppression.

31 March 2020

1 reference

T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura

31 March 2020

1 reference

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

31 March 2020

1 reference

Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.

31 March 2020

1 reference

12 December 2020

Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway

1 reference

12 December 2020

Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg)

1 reference

12 December 2020

Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22.

1 reference

12 December 2020

Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice.

1 reference

12 December 2020

FcγRs in health and disease.

1 reference

12 December 2020

Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.

1 reference

12 December 2020

Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo

1 reference

12 December 2020

Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events

1 reference

12 December 2020

Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. A historical review

1 reference

12 December 2020

Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig

1 reference

12 December 2020

Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient.

1 reference

12 December 2020

Intravenous immunoglobulin: properties, mode of action and practical use in dermatology.

1 reference

12 December 2020

Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI3401

1 reference

PubMed ID

23411799

Dimensions Publication ID

26 July 2017

0 references

1 reference

PubMed ID

23411799